ProQR Non Current Liabilities Total vs Property Plant And Equipment Net Analysis
PRQR Stock | USD 3.84 0.17 4.63% |
ProQR Therapeutics financial indicator trend analysis is much more than just breaking down ProQR Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ProQR Therapeutics is a good investment. Please check the relationship between ProQR Therapeutics Non Current Liabilities Total and its Property Plant And Equipment Net accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.
Non Current Liabilities Total vs Property Plant And Equipment Net
Non Current Liabilities Total vs Property Plant And Equipment Net Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ProQR Therapeutics Non Current Liabilities Total account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have almost identical trend.
The correlation between ProQR Therapeutics' Non Current Liabilities Total and Property Plant And Equipment Net is 0.92. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of ProQR Therapeutics BV, assuming nothing else is changed. The correlation between historical values of ProQR Therapeutics' Non Current Liabilities Total and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of ProQR Therapeutics BV are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Non Current Liabilities Total i.e., ProQR Therapeutics' Non Current Liabilities Total and Property Plant And Equipment Net go up and down completely randomly.
Correlation Coefficient | 0.92 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Non Current Liabilities Total
Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from ProQR Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ProQR Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. As of 11/29/2024, Selling General Administrative is likely to drop to about 12.6 M. In addition to that, Tax Provision is likely to grow to about (74.1 K)
ProQR Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
ProQR Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ProQR Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 117.5M | 98.7M | 209.6M | 171.3M | 137.9M | 108.5M | |
Short Long Term Debt Total | 13.6M | 34.3M | 60.4M | 22.0M | 19.7M | 18.5M | |
Other Current Liab | 9.0M | 7.0M | 14.8M | 10.1M | 8.8M | 6.9M | |
Total Current Liabilities | 11.0M | 10.3M | 27.6M | 21.1M | 34.2M | 35.9M | |
Total Stockholder Equity | 94.3M | 57.1M | 113.8M | 65.5M | 41.4M | 69.4M | |
Net Debt | (98.4M) | (41.6M) | (127.2M) | (72.8M) | (99.2M) | (104.2M) | |
Retained Earnings | (211.7M) | (257.7M) | (317.8M) | (380.7M) | (400.9M) | (380.8M) | |
Accounts Payable | 445K | 221K | 191K | 392K | 1.5M | 1.6M | |
Cash | 112.0M | 75.8M | 187.5M | 94.8M | 118.9M | 92.9M | |
Non Current Assets Total | 2.9M | 18.7M | 18.1M | 16.9M | 16.9M | 17.7M | |
Long Term Debt | 12.7M | 16.2M | 39.3M | 4.3M | 4.3M | 4.1M | |
Cash And Short Term Investments | 112.0M | 75.8M | 187.5M | 94.8M | 118.9M | 92.9M | |
Net Receivables | 850K | 421K | 555K | 57.2M | 1.3M | 1.2M | |
Common Stock Total Equity | 1.5M | 1.7M | 2.2M | 2.2M | 2.5M | 1.3M | |
Common Stock Shares Outstanding | 41.0M | 50.1M | 64.2M | 71.6M | 81.0M | 41.6M | |
Liabilities And Stockholders Equity | 117.5M | 98.7M | 209.6M | 171.3M | 137.9M | 108.5M | |
Non Current Liabilities Total | 12.7M | 31.9M | 68.8M | 85.1M | 62.3M | 65.4M | |
Other Current Assets | 1.5M | (800K) | 3.1M | 2.4M | 793K | 1.2M | |
Other Stockholder Equity | 303.8M | 288.8M | 398.3M | 412.5M | 412.9M | 236.7M | |
Total Liab | 23.7M | 42.2M | 96.4M | 106.2M | 96.5M | 101.3M | |
Total Current Assets | 114.7M | 80.0M | 191.5M | 154.5M | 121.0M | 100.7M | |
Common Stock | 2.2M | 2.2M | 3.0M | 3.4M | 3.9M | 4.1M | |
Net Tangible Assets | 94.3M | 57.1M | 113.8M | 65.5M | 75.3M | 82.9M | |
Property Plant And Equipment Net | 2.4M | 18.6M | 17.5M | 16.2M | 16.9M | 17.7M | |
Current Deferred Revenue | 711K | 700K | 5.1M | 5.8M | 20.6M | 21.6M | |
Property Plant And Equipment Gross | 3.8M | 18.6M | 27.8M | 29.1M | 32.1M | 33.7M | |
Short Long Term Debt | 343K | 1.1M | 4.8M | 2.5M | 2.3M | 2.1M | |
Accumulated Other Comprehensive Income | 151K | (189K) | 30.3M | 30.3M | 26.0M | 27.3M | |
Short Term Debt | 851K | 2.4M | 6.3M | 3.9M | 1.6M | 2.0M | |
Property Plant Equipment | 2.4M | 18.6M | 17.5M | 16.2M | 18.7M | 19.6M | |
Capital Lease Obligations | 508K | 17.0M | 16.3M | 15.2M | 15.4M | 16.2M | |
Inventory | 340K | 379K | 266.5K | 6.9K | 1.0 | 0.95 | |
Net Invested Capital | 107.4M | 74.4M | 157.9M | 72.3M | 45.7M | 69.3M | |
Net Working Capital | 103.7M | 69.7M | 163.9M | 133.3M | 86.8M | 110.0M |
Pair Trading with ProQR Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with ProQR Stock
Moving against ProQR Stock
0.83 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.81 | HLN | Haleon plc | PairCorr |
0.77 | TAK | Takeda Pharmaceutical | PairCorr |
0.74 | ELAN | Elanco Animal Health | PairCorr |
0.67 | RDY | Dr Reddys Laboratories | PairCorr |
The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.
The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ProQR Stock Analysis
When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.